TNF and steatosis: Infliximab, a potent TNF-α neutralizing monoclonal antibody used in the treatment of many chronic inflammatory diseases, improves steatosis and insulin signaling both in genetic and nutritional experimental model of IR, reducing inflammation and increasing hormonal sensitivity (148, 149).